Bayer

Photo: Sushil Dawka / Wikimedia Commons, CC BY-SA 4.0

Bayer agrees to acquire eye-drug developer Perfuse Therapeutics for up to $2.45 billion

Bayer will pay $300 million upfront for the South San Francisco biotech, with the rest tied to milestones. The prize is PER-001, an implant in Phase 2 trials for glaucoma and diabetic retinopathy.